KIF11 (Kinesin-like protein KIF11) variants and mutations
KIF11 (also known as Kinesin-like protein KIF11) is a human protein-coding gene encoding a kinesin-like protein. It powers separation of spindle poles during mitosis and also contributes to microtubule organization in developing tissues. Heterozygous loss-of-function variants can cause microcephaly with or without chorioretinopathy, lymphedema, and developmental impairment. This analysis covers 1,090 KIF11 variants and mutations. Of these, 74% have computational variant effect predictions. Disease context includes microcephaly with or without chorioretinopathy, lymphedema, or intellectual disa, hereditary disease, and Retinal dystrophy. Example KIF11 variants include M1T, M1V, and A2V.
Variant analysis overview
- Gene: KIF11
- Protein: Kinesin-like protein KIF11
- UniProt accession: P52732
- Organism: Homo sapiens
- Variants analyzed: 1090
- Variant scope: all variants
- Completed: 2026-08-20
Variant and mutation evidence
- Variant composition: 889 unspecified-consequence records; 111 missense variants; 70 synonymous variants; 2 in-frame deletions; 9 frameshift variants; 4 splice-region variants; 4 stop-gained variants; 1 substitution
- Prediction scores: 809 variants have prediction scores (74% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: microcephaly with or without chorioretinopathy, lymphedema, or intellectual disa, hereditary disease, Retinal dystrophy, neurodegenerative disease, type 2 diabetes mellitus, microcephaly, asthma, retinitis pigmentosa, Neurodevelopmental delay, microcephaly and chorioretinopathy 1, syndromic retinitis pigmentosa, childhood onset asthma.
Protein structure and variant hotspots
- Protein features: 1 domains; 1 binding sites; 5 post-translational modification sites.
- Structural context: 403 variants have structural context.
- PTM context: 3 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable KIF11 variants
Examples include M1T, M1V, A2V, A2P, A2E, A2A, S3L, S3W. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1T (p.Met1Thr), rs1554858130, ClinGen CA377585494, ClinVar RCV000579126, MutPred 0.98, Pathogenic/Likely pathogenic, not provided
- M1V (p.Met1Val), rs2492454012, ClinGen CA377585489, ClinVar RCV001255743, ClinVar RCV001377705, Pathogenic, not provided
- A2V (p.Ala2Val), rs1340206177, ClinGen CA377585516, NCI-TCGA Cosmic COSV5327, ClinVar RCV002801431, REVEL 0.20, CADD 27.70, Uncertain significance, not provided
- A2P (p.Ala2Pro), gnomAD 10-92593379-G-C, REVEL 0.21, CADD 29.50
- A2E (p.Ala2Glu), gnomAD 10-92593380-C-A, REVEL 0.24, CADD 27.00
- A2A (p.Ala2Ala), rs1437550192, gnomAD 10-92593381-G-A, CADD 15.90
- S3L (p.Ser3Leu), rs1276986880, NCI-TCGA Cosmic COSV5327, TOPMed rs1276986880, gnomAD rs1276986880, REVEL 0.18, CADD 24.60, Variant assessed as somatic; moderate impact.
- S3W (p.Ser3Trp), TOPMed rs1276986880, gnomAD rs1276986880
- S3S (p.Ser3Ser), rs776766098, gnomAD 10-92593384-G-A, CADD 11.30
- Q4L (p.Gln4Leu), gnomAD 10-92593386-A-T, REVEL 0.26, CADD 24.80
- Q4R (p.Gln4Arg), gnomAD 10-92593386-A-G, REVEL 0.22, CADD 26.00
- Q4Q (p.Gln4Gln), rs376818610, gnomAD 10-92593387-G-A, CADD 13.10
- Q4H (p.Gln4His), gnomAD 10-92593387-G-T, REVEL 0.24, CADD 23.40
- P5L (p.Pro5Leu), Ensembl rs1844253480
- P5S (p.Pro5Ser), Ensembl rs1589582868, REVEL 0.16, CADD 21.40
- P5P (p.Pro5Pro), gnomAD 10-92593390-A-G, CADD 14.70
- N6D (p.Asn6Asp), TOPMed rs1285620374, gnomAD rs1285620374, REVEL 0.13, CADD 24.30
- N6K (p.Asn6Lys), TOPMed rs1295002402
- N6S (p.Asn6Ser), gnomAD 10-92593392-A-G, REVEL 0.07, CADD 18.60
- S7P (p.Ser7Pro), gnomAD rs1355197212, REVEL 0.21, CADD 23.00
- S7L (p.Ser7Leu), gnomAD 10-92593395-C-T, REVEL 0.17, CADD 24.70
- S7S (p.Ser7Ser), rs1844253594, gnomAD 10-92593396-G-C, CADD 9.15
- S8Y (p.Ser8Tyr), gnomAD 10-92593398-C-A, REVEL 0.21, CADD 23.30
- S8C (p.Ser8Cys), gnomAD 10-92593398-C-G, REVEL 0.18, CADD 22.60
- S8S (p.Ser8Ser), rs1213893848, gnomAD 10-92593399-T-C, CADD 8.29
- A9G (p.Ala9Gly), rs764844734, ClinGen CA5603881, ClinVar RCV001325601, ExAC rs764844734, REVEL 0.04, CADD 18.40, Uncertain significance, not provided
- A9T (p.Ala9Thr), gnomAD 10-92593400-G-A, REVEL 0.04, CADD 21.10
- A9A (p.Ala9Ala), rs1373911610, gnomAD 10-92593402-G-A, CADD 13.80
- K10R (p.Lys10Arg), Ensembl rs967300114
- K10K (p.Lys10Lys), rs1035422524, gnomAD 10-92593405-G-A, CADD 15.20
- K10N (p.Lys10Asn), gnomAD 10-92593405-G-T, REVEL 0.16, CADD 23.70
- K11E (p.Lys11Glu), gnomAD 10-92593406-A-G, REVEL 0.28, CADD 31.00
- K11K (p.Lys11Lys), rs1844253784, gnomAD 10-92593408-G-A, CADD 14.50
- K12R (p.Lys12Arg), gnomAD 10-92593410-A-G, REVEL 0.16, CADD 23.30
- K12K (p.Lys12Lys), rs1844253815, gnomAD 10-92593411-A-G, CADD 14.90
- E13D (p.Glu13Asp), gnomAD rs1844253914, REVEL 0.10, CADD 7.52
- E13K (p.Glu13Lys), gnomAD 10-92593412-G-A, REVEL 0.13, CADD 25.50
- E14A (p.Glu14Ala), rs1200677717, ClinGen CA377585705, ClinVar RCV002650766, TOPMed rs1200677717, REVEL 0.20, CADD 25.00, Likely benign, not provided
- E14G (p.Glu14Gly), TOPMed rs1200677717, gnomAD rs1200677717, REVEL 0.34, CADD 27.50, Likely benign
- E14del (p.Glu14del), rs1490416728, gnomAD 10-92593411-AGAG-, CADD 22.30
- E14K (p.Glu14Lys), gnomAD 10-92593415-G-A, REVEL 0.18, CADD 25.70
- K15N (p.Lys15Asn), TOPMed rs1169320280
- K15K (p.Lys15Lys), gnomAD 10-92593420-G-A, CADD 13.20
- G16E (p.Gly16Glu), gnomAD rs1244797581
- G16G (p.Gly16Gly), gnomAD 10-92593423-G-A, CADD 14.10
- K17R (p.Lys17Arg), gnomAD 10-92593425-A-G, REVEL 0.20, CADD 20.80
- K17N (p.Lys17Asn), gnomAD 10-92593426-G-T, REVEL 0.29, CADD 32.00
- N18S (p.Asn18Ser), NCI-TCGA Cosmic COSV9958, Variant assessed as somatic; moderate impact.
- N18N (p.Asn18Asn), rs772804375, gnomAD 10-92593429-C-T, CADD 13.90
- I19V (p.Ile19Val), gnomAD rs1159055283
- I19T (p.Ile19Thr), gnomAD 10-92593431-T-C, REVEL 0.84, CADD 31.00
- I19I (p.Ile19Ile), rs1844254201, gnomAD 10-92593432-C-A, CADD 15.50
- Q20R (p.Gln20Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- Q20Q (p.Gln20Gln), gnomAD 10-92593435-G-A, CADD 14.80
- V21G (p.Val21Gly), Ensembl rs1589582916
- V21M (p.Val21Met), gnomAD 10-92593436-G-A, REVEL 0.79, CADD 32.00
- V22M (p.Val22Met), TOPMed rs1460109490
- V22L (p.Val22Leu), gnomAD 10-92593439-G-T, REVEL 0.44, CADD 31.00
- V23L (p.Val23Leu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- V23G (p.Val23Gly), gnomAD 10-92593443-T-G, REVEL 0.83, CADD 32.00
- V23V (p.Val23Val), rs1372121391, gnomAD 10-92593444-G-C, CADD 14.00
- C25A (p.Cys25Ala), rs748203155, gnomAD 10-92593447-AT-A, CADD 32.00
- C25C (p.Cys25Cys), gnomAD 10-92593450-C-T, CADD 26.10
- R26G (p.Arg26Gly), rs2135892544, ClinGen CA377585946, ClinVar RCV002007699, Ensembl rs2135892544, MutPred 0.88, Pathogenic/Likely pathogenic, not provided
- R26I (p.Arg26Ile), rs1564700259, ClinGen CA377585955, ClinVar RCV000761738, Ensembl rs1564700259, MutPred 0.88, Uncertain significance, not provided
- R26K (p.Arg26Lys), gnomAD 10-92593452-G-A, REVEL 0.81, CADD 36.00
- P27P (p.Pro27Pro), rs1340530084, gnomAD 10-92606268-A-G, CADD 8.99
- F28L (p.Phe28Leu), TOPMed rs1242282875, gnomAD rs1242282875, REVEL 0.50, CADD 23.20
- N29D (p.Asn29Asp), gnomAD 10-92606272-A-G, REVEL 0.75, CADD 26.90
- N29K (p.Asn29Lys), gnomAD 10-92606274-T-G, REVEL 0.65, CADD 24.00
- L30* (p.Leu30Ter), rs2492475559, ClinGen CA377587695, ClinVar RCV002789990, Likely pathogenic
- A31E (p.Ala31Glu), gnomAD 10-92606279-C-A, REVEL 0.20, CADD 22.80
- E32K (p.Glu32Lys), gnomAD 10-92606281-G-A, REVEL 0.85, CADD 31.00
- E32E (p.Glu32Glu), rs1844429878, gnomAD 10-92606283-G-A, CADD 7.78
- R33Q (p.Arg33Gln), rs1282064424, ClinGen CA377587715, ClinVar RCV002696285, gnomAD rs1282064424, REVEL 0.35, CADD 24.30, Likely benign, not provided
- R33W (p.Arg33Trp), rs773934211, ClinGen CA5603905, ClinVar RCV002011231, ExAC rs773934211, REVEL 0.64, CADD 26.00, Uncertain significance, not provided
- R33P (p.Arg33Pro), gnomAD 10-92606285-G-C, REVEL 0.63, CADD 27.00
- A35A (p.Ala35Ala), rs759170504, gnomAD 10-92606292-T-C, CADD 13.10
- S36R (p.Ser36Arg), 1000Genomes rs199698837, ExAC rs199698837, TOPMed rs199698837, gnomAD rs199698837, REVEL 0.33, CADD 9.37, Likely benign
- S36G (p.Ser36Gly), gnomAD 10-92606293-A-G, REVEL 0.26, CADD 20.20
- S36N (p.Ser36Asn), gnomAD 10-92606294-G-A, REVEL 0.19, CADD 4.74
- S36I (p.Ser36Ile), gnomAD 10-92606294-G-T, REVEL 0.28, CADD 21.90
- S36S (p.Ser36Ser), rs199698837, gnomAD 10-92606295-C-T, CADD 1.82
- A37D (p.Ala37Asp), gnomAD rs1456353610
- A37S (p.Ala37Ser), ExAC rs754165708, TOPMed rs754165708, gnomAD rs754165708, REVEL 0.22, CADD 18.70
- A37T (p.Ala37Thr), rs754165708, NCI-TCGA Cosmic COSV5326, ExAC rs754165708, TOPMed rs754165708, REVEL 0.31, CADD 25.80, Variant assessed as somatic; moderate impact.
- A37A (p.Ala37Ala), gnomAD 10-92606298-C-T, CADD 13.00
- H38Y (p.His38Tyr), TOPMed rs1844430207, gnomAD rs1844430207, REVEL 0.23, CADD 16.90, Uncertain significance, Inborn genetic diseases
- H38Q (p.His38Gln), gnomAD 10-92606301-T-G, REVEL 0.27, CADD 24.00
- H38H (p.His38His), rs765785937, gnomAD 10-92606301-T-C, CADD 11.10
- S39S (p.Ser39Ser), gnomAD 10-92606304-A-C, CADD 11.20
- I40M (p.Ile40Met), rs1844430333, ClinGen CA377587762, ClinVar RCV001067415, TOPMed rs1844430333, REVEL 0.43, CADD 20.30, Uncertain significance, not provided
- I40V (p.Ile40Val), rs561133245, ClinGen CA5603911, ClinVar RCV003397673, 1000Genomes rs561133245, REVEL 0.22, CADD 12.60, Uncertain significance, KIF11-related disorder
- I40T (p.Ile40Thr), gnomAD 10-92606306-T-C, REVEL 0.56, CADD 26.40
- V41A (p.Val41Ala), gnomAD rs1424458022, REVEL 0.77, CADD 27.00
- V41I (p.Val41Ile), gnomAD rs1458407202, REVEL 0.33, CADD 21.10, Uncertain significance
- V41L (p.Val41Leu), rs1458407202, ClinGen CA377587764, ClinVar RCV001763077, gnomAD rs1458407202, MutPred 0.69, Uncertain significance, not provided
- V41V (p.Val41Val), rs373135960, gnomAD 10-92606310-A-G, CADD 8.15
- E42A (p.Glu42Ala), Ensembl rs1435229320
- D44E (p.Asp44Glu), rs1564704121, ClinGen CA377587791, ClinVar RCV001765941, Ensembl rs1564704121, REVEL 0.08, CADD 14.80, Conflicting interpretations, not provided
- D44G (p.Asp44Gly), rs1844430488, ClinGen CA377587789, ClinVar RCV001331250, Ensembl rs1844430488, MutPred 0.45, Uncertain significance, Microcephaly with or without chorioretinopathy, lymphedema, or intellectual disa
- P45T (p.Pro45Thr), TOPMed rs1844430539
- P45A (p.Pro45Ala), gnomAD 10-92606320-C-G, REVEL 0.13, CADD 3.43
- P45P (p.Pro45Pro), gnomAD 10-92606322-T-C, CADD 3.08
- V46L (p.Val46Leu), gnomAD 10-92606323-G-C, REVEL 0.21, CADD 8.35
- V46V (p.Val46Val), gnomAD 10-92606325-A-G, CADD 6.42
- R47* (p.Arg47Ter), rs1227480400, ClinGen CA377587806, ClinVar RCV000578602, ClinVar RCV001255733, MutPred 0.35, Pathogenic
- R47G (p.Arg47Gly), TOPMed rs1227480400
- R47Q (p.Arg47Gln), ExAC rs780120726, gnomAD rs780120726, REVEL 0.39, CADD 29.80
- V50I (p.Val50Ile), ESP rs376032374, ExAC rs376032374, TOPMed rs376032374, gnomAD rs376032374, REVEL 0.18, CADD 19.70, Likely benign
- V50L (p.Val50Leu), rs376032374, ClinGen CA5603914, ClinVar RCV001346277, ESP rs376032374, REVEL 0.26, CADD 21.00, Likely benign, not provided
- V50A (p.Val50Ala), gnomAD 10-92606336-T-C, REVEL 0.62, CADD 26.60
- S51G (p.Ser51Gly), rs1844430675, ClinGen CA377587829, ClinVar RCV001331251, Ensembl rs1844430675, REVEL 0.42, CADD 25.40, Uncertain significance, Microcephaly with or without chorioretinopathy, lymphedema, or intellectual disa
- S51N (p.Ser51Asn), rs1844430705, ClinGen CA377587832, ClinVar RCV003865170, TOPMed rs1844430705, MutPred 0.39, Uncertain significance, not provided
- S51S (p.Ser51Ser), rs781156148, gnomAD 10-92606340-T-C, CADD 9.97
- R53* (p.Arg53Ter), rs2135900558, ClinGen CA377587845, ClinVar RCV001382096, ClinVar RCV003314007, Pathogenic
- R53Q (p.Arg53Gln), gnomAD rs1426194232, REVEL 0.33, CADD 27.80
- R53L (p.Arg53Leu), gnomAD 10-92606345-G-T, REVEL 0.44, CADD 28.60
- T54A (p.Thr54Ala), gnomAD 10-92606347-A-G, REVEL 0.32, CADD 23.50
- G55A (p.Gly55Ala), rs769680276, ClinGen CA5603918, ClinVar RCV003244107, ExAC rs769680276, REVEL 0.12, CADD 21.40, Uncertain significance, Inborn genetic diseases
- G55R (p.Gly55Arg), ExAC rs748004032, gnomAD rs748004032
- G56R (p.Gly56Arg), gnomAD 10-92606353-G-C, REVEL 0.26, CADD 27.50
- L57M (p.Leu57Met), gnomAD 10-92606356-T-A, REVEL 0.21, CADD 13.80
- L57L (p.Leu57Leu), rs1403627656, gnomAD 10-92606356-T-C, CADD 8.12
- A58S (p.Ala58Ser), Ensembl rs1844430936, REVEL 0.13, CADD 15.40
- A58T (p.Ala58Thr), Ensembl rs1844430936, REVEL 0.09, CADD 14.60
- A58A (p.Ala58Ala), rs777923201, gnomAD 10-92606361-T-A, CADD 3.23
- D59N (p.Asp59Asn), NCI-TCGA Cosmic COSV5327, REVEL 0.39, CADD 28.50, Variant assessed as somatic; moderate impact.
- D59D (p.Asp59Asp), rs1358678267, gnomAD 10-92606364-C-T, CADD 9.52
- D59E (p.Asp59Glu), gnomAD 10-92606364-C-G, REVEL 0.35, CADD 16.50
- K60M (p.Lys60Met), rs1298166671, ClinGen CA377587934, ClinVar RCV001817689, ClinVar RCV004770217, REVEL 0.71, CADD 28.50, Uncertain significance, not provided; not specified
- K60T (p.Lys60Thr), TOPMed rs1298166671, gnomAD rs1298166671, REVEL 0.63, CADD 27.20, Uncertain significance
- K60R (p.Lys60Arg), gnomAD 10-92606366-A-G, REVEL 0.40, CADD 26.90
- K60K (p.Lys60Lys), rs184049283, gnomAD 10-92606367-G-A, CADD 8.89
- S61R (p.Ser61Arg), Ensembl rs1564704148
- S61I (p.Ser61Ile), gnomAD 10-92606369-G-T, REVEL 0.13, CADD 23.10
- S61N (p.Ser61Asn), gnomAD 10-92606369-G-A, REVEL 0.09, CADD 22.60
- S61S (p.Ser61Ser), gnomAD 10-92606370-C-T, CADD 10.10
- S62S (p.Ser62Ser), gnomAD 10-92606373-A-C, CADD 4.19
- R63M (p.Arg63Met), NCI-TCGA Cosmic COSV9958, Variant assessed as somatic; moderate impact.
- K64K (p.Lys64Lys), rs1218895422, gnomAD 10-92606379-A-G, CADD 3.35
- T65A (p.Thr65Ala), rs200410468, ClinGen CA5603922, ClinVar RCV001237555, ClinVar RCV001331252, REVEL 0.59, CADD 25.10, Conflicting interpretations, Inborn genetic diseases; not specified; not provided
- T65H (p.Thr65His), gnomAD 10-92606376-GA-G, CADD 26.40
- T65del (p.Thr65del), gnomAD 10-92606378-AAAC-, CADD 18.00
- T65I (p.Thr65Ile), gnomAD 10-92606381-C-T, REVEL 0.54, CADD 23.90
- T65T (p.Thr65Thr), rs759142342, gnomAD 10-92606382-A-G, CADD 4.38
- Y66Y (p.Tyr66Tyr), rs2135900586, gnomAD 10-92606385-C-T, CADD 0.09
- T67A (p.Thr67Ala), gnomAD 10-92606386-A-G, REVEL 0.56, CADD 23.20
- F68S (p.Phe68Ser), NCI-TCGA TCGA novel, Ensembl rs1589590275, Variant assessed as somatic; moderate impact.
- F68F (p.Phe68Phe), gnomAD 10-92606391-T-C, CADD 10.10
- D69A (p.Asp69Ala), rs2135900590, ClinGen CA377588070, ClinVar RCV001754001, Ensembl rs2135900590, MutPred 0.95, Uncertain significance, not provided
- D69N (p.Asp69Asn), rs796052144, ClinGen CA204069, ClinVar RCV000190130, ClinVar RCV006555649, REVEL 0.74, CADD 27.70, Uncertain significance, not provided
- M70T (p.Met70Thr), Ensembl rs1844431429, Uncertain significance, Microcephaly with or without chorioretinopathy, lymphedema, or intellectual disa
- M70V (p.Met70Val), ExAC rs771667854, gnomAD rs771667854
- V71G (p.Val71Gly), Ensembl rs1589590438, REVEL 0.93, CADD 32.00
- V71L (p.Val71Leu), Ensembl rs1554859335, REVEL 0.78, CADD 33.00
- V71M (p.Val71Met), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- V71V (p.Val71Val), rs775193169, gnomAD 10-92606621-G-T, CADD 2.98
- F72L (p.Phe72Leu), Ensembl rs182023792, REVEL 0.90, CADD 26.30, Likely benign
- F72S (p.Phe72Ser), gnomAD 10-92606623-T-C, REVEL 0.87, CADD 26.60
- F72F (p.Phe72Phe), rs182023792, gnomAD 10-92606624-T-C, CADD 10.70
- G73E (p.Gly73Glu), NCI-TCGA Cosmic COSV5327, Variant assessed as somatic; moderate impact.
- G73F (p.Gly73Phe), rs1554859337, gnomAD 10-92606619-G-GTT, CADD 27.80
- G73* (p.Gly73Ter), gnomAD 10-92606625-G-T, CADD 38.00
- G73R (p.Gly73Arg), gnomAD 10-92606625-G-A, REVEL 0.87, CADD 29.90
- G73V (p.Gly73Val), gnomAD 10-92606626-G-T, REVEL 0.90, CADD 28.10
- G73G (p.Gly73Gly), gnomAD 10-92606627-A-T, CADD 10.30
- A74T (p.Ala74Thr), rs369196517, ClinGen CA5603955, ClinVar RCV002571115, ExAC rs369196517, REVEL 0.23, CADD 17.80, Likely benign, not provided
- A74S (p.Ala74Ser), gnomAD 10-92606628-G-T, REVEL 0.14, CADD 15.70
- A74V (p.Ala74Val), gnomAD 10-92606629-C-T, REVEL 0.29, CADD 18.80
- A74E (p.Ala74Glu), gnomAD 10-92606629-C-A, REVEL 0.23, CADD 21.00
- S75P (p.Ser75Pro), gnomAD 10-92606631-T-C, REVEL 0.44, CADD 22.20
- S75A (p.Ser75Ala), gnomAD 10-92606631-T-G, REVEL 0.14, CADD 14.10
- S75Y (p.Ser75Tyr), gnomAD 10-92606632-C-A, REVEL 0.32, CADD 24.40
- S75F (p.Ser75Phe), gnomAD 10-92606632-C-T, REVEL 0.34, CADD 25.00
- S75S (p.Ser75Ser), gnomAD 10-92606633-T-A, CADD 6.00
- T76A (p.Thr76Ala), rs770145180, ClinGen CA5603956, ClinVar RCV003672241, ExAC rs770145180, REVEL 0.28, CADD 17.90, Uncertain significance, not provided
- T76S (p.Thr76Ser), gnomAD 10-92606634-A-T, REVEL 0.30, CADD 20.70
- T76I (p.Thr76Ile), gnomAD 10-92606635-C-T, REVEL 0.63, CADD 26.00
- T76N (p.Thr76Asn), gnomAD 10-92606635-C-A, REVEL 0.60, CADD 25.10
Public KIF11 analysis runs
- KIF11 analysis run — KIF11 (1,090 variants) — completed 2026-08-20